Sphingosine-1-Phosphate Receptor Modulators in Animal and Cell Studies
Studies show that sphingosine-1-phosphate (S1P) receptor modulators enhance oligodendrocyte precursor cell (OPC) differentiation and process extension in cells. Animal models indicate these modulators can increase remyelination, improve myelin protein expression, and facilitate functional recovery. Imaging in MS patients suggests these effects could translate to increased myelin repair over time.
- Tags
- #MSResearch
- Most relevant to
- —
Why it matters
These findings suggest that S1P receptor modulators may play a role in promoting myelin repair, a critical aspect of recovery in multiple sclerosis. However, the studies do not confirm definitive treatment outcomes or human efficacy.
What this does not prove
This review summarizes various studies but does not establish conclusive outcomes or mechanisms. Further research is needed to better understand the specific effects of S1P receptor modulation.
Next milestone
No next milestone was established from the available source.
Study facts
- Study design
- Not reported
- Participants / samples
- Not reported
- Randomised
- Not reported
- Controlled
- Not reported
- Primary endpoint met
- Not reported
- Relevant MS type
- Not reported
- Publication date
- 2026-09-09
- Evidence reviewed
- Abstract only
- Regulatory approval
- Not reported
- Research areas
- Not classified
Original sources
- Primary evidenceEffects of sphingosine-1-phosphate receptor modulators on remyelination in multiple sclerosis: evidence from in vitro experiments, animal models and human studies. ↗DOI: 10.3389/fimmu.2026.1895118
Supporting passages (6)
subjectsTitle: Effects of sphingosine-1-phosphate receptor modulators on remyelination in multiple sclerosis: evidence from in vitro experiments, animal models and human studies.
regulatory approval detailsThere are four S1P modulators currently approved by the Food and Drug Administration/European Medical Agency (FDA/EMA): fingolimod, siponimod, ponesimod, and ozanimod.
publication date2026-09-09
interventionSphingosine-1-phosphate (S1P) receptor modulators are a class of therapeutic agents used for the treatment of multiple sclerosis (MS).
findingsIn vitro studies show enhanced OPC differentiation and process extension, while in vivo models demonstrate increased remyelination, improved myelin protein expression, and functional recovery.
limitationsTitle: Effects of sphingosine-1-phosphate receptor modulators on remyelination in multiple sclerosis: evidence from in vitro experiments, animal models and human studies.
AI assessment, not yet reviewed by a person · version 1 · Community votes are separate from evidence review.